MAIA

SEC source: 0001878313-26-000096 · form4.xml · derivative · entry 1

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,012

Underlying: Common Stock · 32,012 shares

Expires 2036-09-30

F1 · derivative.exercise_date: The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-26-000095 · form4.xml · derivative · entry 1

CHAOUKI STEVEN M · CIK 0001776865 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,774

Underlying: Common Stock · 32,774 shares

Expires 2036-09-30

F1 · derivative.exercise_date: The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-26-000097 · form4.xml · derivative · entry 1

Louie Ngar Yee · CIK 0001913264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,634

Underlying: Common Stock · 39,634 shares

Expires 2036-09-30

F1 · derivative.exercise_date: The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-26-000099 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 38,871

Underlying: Common Stock · 38,871 shares

Expires 2036-09-30

F1 · derivative.exercise_date: The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.direct: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-26-000098 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,536

Underlying: Common Stock · 33,536 shares

Expires 2036-09-30

F1 · derivative.exercise_date: The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-26-000100 · form4.xml · derivative · entry 1

Theagene Jean-Manasse · CIK 0001969857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,012

Underlying: Common Stock · 32,012 shares

Expires 2036-09-30

F1 · derivative.exercise_date: The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-26-000087 · form4.xml · nonDerivative · entry 1

Vitoc Vlad · CIK 0001913257 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,049,121

SEC source: 0001878313-26-000084 · form4.xml · nonDerivative · entry 1

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 773,296

SEC source: 0001878313-26-000082 · form4.xml · nonDerivative · entry 3

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 735,701

SEC source: 0001878313-26-000082 · form4.xml · nonDerivative · entry 2

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 689,081

SEC source: 0001878313-26-000082 · form4.xml · nonDerivative · entry 1

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 610,842

SEC source: 0001878313-26-000079 · form4.xml · nonDerivative · entry 1

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 601,911

SEC source: 0001878313-26-000077 · form4.xml · nonDerivative · entry 1

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 600,117

SEC source: 0001878313-26-000073 · form4.xml · derivative · entry 1

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,355

Underlying: Common Stock · 26,355 shares

Expires 2036-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-26-000072 · form4.xml · derivative · entry 1

Louie Ngar Yee · CIK 0001913264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,630

Underlying: Common Stock · 32,630 shares

Expires 2036-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-26-000074 · form4.xml · derivative · entry 1

CHAOUKI STEVEN M · CIK 0001776865 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,982

Underlying: Common Stock · 26,982 shares

Expires 2036-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-26-000071 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,610

Underlying: Common Stock · 27,610 shares

Expires 2036-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-26-000070 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 32,003

Underlying: Common Stock · 32,003 shares

Expires 2036-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-26-000069 · form4.xml · derivative · entry 1

Theagene Jean-Manasse · CIK 0001969857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,355

Underlying: Common Stock · 26,355 shares

Expires 2036-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-26-000062 · form4.xml · nonDerivative · entry 1

Vitoc Vlad · CIK 0001913257 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 976,121

F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.3634 to $1.4150, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

SEC source: 0001878313-26-000061 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,519,178

F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.32 to $1.40, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-26-000060 · form4.xml · nonDerivative · entry 1

Gryaznov Sergei · CIK 0001913228 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,511

SEC source: 0001878313-26-000053 · form4.xml · derivative · entry 1

Vitoc Vlad · CIK 0001913257 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 800,000

Underlying: Common Stock · 800,000 shares

Expires 2036-05-29

F1 · derivative.exercise_date: The stock options, granted on May 29, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.

SEC source: 0001878313-26-000051 · form4.xml · derivative · entry 1

Gryaznov Sergei · CIK 0001913228 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2036-05-29

F1 · derivative.exercise_date: The stock options, granted on May 29, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.

SEC source: 0001878313-26-000049 · form4.xml · derivative · entry 1

Himmelreich Jeffrey C · CIK 0002001189 · Head of Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2036-05-29

F1 · derivative.exercise_date: The stock options, granted on May 29, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.

SEC source: 0001878313-26-000046 · form4.xml · derivative · entry 1

Gryaznov Sergei · CIK 0001913228 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2036-04-10

F1 · derivative.exercise_date: The stock options, granted on April 10, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.

SEC source: 0001878313-26-000047 · form4.xml · derivative · entry 1

Vitoc Vlad · CIK 0001913257 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 800,000

Underlying: Common Stock · 800,000 shares

Expires 2036-04-10

F1 · derivative.exercise_date: The stock options, granted on April 10, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.

SEC source: 0001878313-26-000044 · form4.xml · derivative · entry 1

Himmelreich Jeffrey C · CIK 0002001189 · Head of Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2036-04-10

F1 · derivative.exercise_date: The stock options, granted on April 10, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.

SEC source: 0001878313-26-000037 · form4.xml · derivative · entry 1

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,258

Underlying: Common Stock · 27,258 shares

Expires 2036-03-31

F1 · derivative.exercise_date: The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-26-000039 · form4.xml · derivative · entry 1

CHAOUKI STEVEN M · CIK 0001776865 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,907

Underlying: Common Stock · 27,907 shares

Expires 2036-03-31

F1 · derivative.exercise_date: The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-26-000035 · form4.xml · derivative · entry 1

Louie Ngar Yee · CIK 0001913264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,748

Underlying: Common Stock · 33,748 shares

Expires 2036-03-31

F1 · derivative.exercise_date: The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-26-000033 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,556

Underlying: Common Stock · 28,556 shares

Expires 2036-03-31

F1 · derivative.exercise_date: The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-26-000031 · form4.xml · derivative · entry 1

Theagene Jean-Manasse · CIK 0001969857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,258

Underlying: Common Stock · 27,258 shares

Expires 2036-03-31

F1 · derivative.exercise_date: The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-26-000029 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 33,099

Underlying: Common Stock · 33,099 shares

Expires 2036-03-31

F1 · derivative.exercise_date: The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.direct: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-26-000018 · form4.xml · derivative · entry 1

Theagene Jean-Manasse · CIK 0001969857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,060

Underlying: Common Stock · 24,060 shares

Expires 2035-12-31

F1 · derivative.exercise_date: The stock options, granted on December 31, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-26-000016 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 29,216

Underlying: Common Stock · 29,216 shares

Expires 2035-12-31

F1 · derivative.exercise_date: The stock options, granted on December 31, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.direct: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-26-000014 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,206

Underlying: Common Stock · 25,206 shares

Expires 2035-12-31

F1 · derivative.exercise_date: The stock options, granted on December 31, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-26-000012 · form4.xml · derivative · entry 1

Louie Ngar Yee · CIK 0001913264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,789

Underlying: Common Stock · 29,789 shares

Expires 2035-12-31

F1 · derivative.exercise_date: The stock options, granted on December 31, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-26-000010 · form4.xml · derivative · entry 1

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,060

Underlying: Common Stock · 24,060 shares

Expires 2035-12-31

F1 · derivative.exercise_date: The stock options, granted on December 31, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-26-000008 · form4.xml · derivative · entry 1

CHAOUKI STEVEN M · CIK 0001776865 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,633

Underlying: Common Stock · 24,633 shares

Expires 2035-12-31

F1 · derivative.exercise_date: The stock options, granted on December 31, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001878313-25-000073 · form4.xml · derivative · entry 5

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 57,189

Underlying: Common Stock · 57,189 shares

Expires 2028-12-22

F6 · shares: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on December 22, 2025. The options are exercisable beginning on the sixth month anniversary of the issuance date and expire 3-years after the initial issuance date.

F7 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-25-000073 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,421,478

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on December 22, 2025.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-25-000071 · form4.xml · derivative · entry 2

CHAOUKI STEVEN M · CIK 0001776865 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,849

Underlying: Common Stock · 40,849 shares

Expires 2028-12-22

F2 · shares: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on December 22, 2025. The options are exercisable beginning on the six month anniversary of the issuance date and expire 3-years after the initial issuance date.

SEC source: 0001878313-25-000071 · form4.xml · nonDerivative · entry 1

CHAOUKI STEVEN M · CIK 0001776865 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 151,873

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on December 22, 2025.

SEC source: 0001878313-25-000069 · form4.xml · derivative · entry 2

Louie Ngar Yee · CIK 0001913264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,699

Underlying: Common Stock · 81,699 shares

Expires 2028-12-22

F2 · shares: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on December 22, 2025. The options are exercisable beginning on the six month anniversary of the issuance date and expire 3-years after the initial issuance date.

SEC source: 0001878313-25-000069 · form4.xml · nonDerivative · entry 1

Louie Ngar Yee · CIK 0001913264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,248,888

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on December 22, 2025

SEC source: 0001878313-25-000063 · form4.xml · nonDerivative · entry 3

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 4,580

F3 · ownership.nature: These securities are beneficially owned by Mr. Smith through the Blake Sarai Teitei Smith IL Unif Trns Min Act. They are beneficially owned by Mr. Smith's family member. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001878313-25-000063 · form4.xml · nonDerivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 4,580

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through the Gage Quentin Smith IL Unif Trns Min Act. They are beneficially owned by Mr. Smith's family member. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001878313-25-000063 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 4,580

F1 · ownership.nature: These securities are beneficially owned by Mr. Smith through the Travis Deo Zai Zai Smith IL Unif Trns Min Act. They are beneficially owned by Mr. Smith's family member. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001878313-25-000056 · form4.xml · nonDerivative · entry 1

Vitoc Vlad · CIK 0001913257 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 881,421

F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.1283 to $1.1416, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.